EUCTR2009-012325-11-DK进行中（未招募）不适用
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) - CS36
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 380
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Signed informed consent obtained before any trial-related activity is performed
- •2.Men, aged 50 or older
- •3.Clinical signs and symptoms of BPH for =6 months
- •4.Moderate to severe LUTS at screening, as defined by IPSS =13
- •5.An IPSS QoL score of =3 at screening
- •6.Prostate specific antigen (PSA) at screening =10 ng/mL (responsibility of the Investigator to rule out prostate cancer when PSA is >4 ng/mL, except in the USA where patients with a PSA >4 and =10 ng/mL should undergo a prostatic biopsy or have a negative prostatic biopsy within 12 months prior to participation in the trial)
- •7.Maximum urinary flow (Qmax) ranging between 5 to 15 mL/second with a minimum voided volume >125 mL at screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Post void residual volume (PVR) >250 mL
- •2.Stone in the bladder or urethra causing symptoms
- •3.Acute or chronic prostatitis
- •4.Interstitial cystitis / painful bladder syndrome
- •5.Acute or recurrent urinary tract infections
- •6.History of acute urinary retention (AUR)
- •7.Lower urinary tract instrumentation (including prostate biopsy) within 30 days of dosing at Visit 2
- •8.Clinical evidence of any of the following urinary tract conditions:
- •a) Mullerian duct cysts
- •b) Atonic, decompensated, or hypocontractile bladder
- •c) Detrusor-sphincter dyssynergia (contraction of the detrusor without sphincter relaxation)
- •9.History of any of the following pelvic conditions:
- •a) Pelvic surgery or any other pelvic procedure, including radical prostatectomy, pelvic surgery for removal of malignancy, or open lower colonic or rectal surgery
- •b) Pelvic radiotherapy
- •c) Any prior surgical procedure of the urinary tract, including minimally invasive LUTS/BPH therapies
- •d) Lower tract malignancy or trauma
- •10.Clinically significant microscopic hematuria at screening
- •11.History of significant renal insufficiency, defined as receiving renal dialysis or having an estimated creatinine clearance <30 mL/minute at screening
- •12.Systolic blood pressure >180 or <90 mmHg or diastolic blood pressure >110 or <50 mmHg at screening or malignant hypertension
- •13.Any causes other than BPH, which may affect evaluation of symptoms of urine flow (e.g. neurogenic bladder, bladder neck contracture, urethral stricture, and bladder malignancy) as judged by the Investigator
- •14.Use of any prohibited therapies*
- •15.Elevated liver function tests at screening:
- •a) Aspartate aminotransferase (AST), alanine aminotranseferase (ALT), alkaline phosphatase (ALP) >2 times the upper limit of normal
- •b) Total bilirubin >1.5 times the upper limit of normal
- •16.QTc interval on the screening ECG >450 ms, or a family history of long QT syndrome
- •17.Any clinically significant disorder (other than BPH) including, but not limited to, renal, haematological, gastrointestinal, endocrine, cardiac, neurological, or psychiatric disease, or any other condition, which may affect the patient’s health or the outcome of the trial as judged by the Investigator
- •18.Diagnosed cancer within the last 5 years except for adequately managed basal cell carcinoma and squamous cell carcinoma of the skin
- •19.History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema
- •20.Mental incapacity or language barrier precluding adequate understanding or co-operation
- •21.History or current evidence of drug, alcohol, or substance abuse within 6 months prior to screening
- •22.Hypersensitivity towards any component of the investigational medicinal product (IMP)
- •23.Previous participation in any degarelix trial
研究者
相似试验
进行中（未招募）
1 期
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) - CS36EUCTR2009-012325-11-GBFerring Pharmaceuticals A/S380
进行中（未招募）
不适用
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) - CS36Bening Prostate HyperplasiaMedDRA version: 12.0Level: LLTClassification code 10014840Term: Enlarged prostate (benign)EUCTR2009-012325-11-CZFerring Pharmaceuticals A/S380
进行中（未招募）
不适用
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) - CS36EUCTR2009-012325-11-BEFerring Pharmaceuticals A/S380
已完成
2 期
A multi-center, randomized, double-blind, dose-parallel, placebo-controlled phase II clinical trial to evaluate the effectiveness and safety of Ganmao Shuangjie Granules in the treatment of influenza (external cold, internal heat syndrome)influenza (external cold, internal heat syndromeITMCTR2100005067Beijing Hospital of Traditional Chinese Medicine
进行中（未招募）
不适用
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys and Copegus versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection. - NDChronic Hepatitis C (CHC) Genotype 1 or 4MedDRA version: 12.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2008-008258-21-ITF. Hoffmann - La Roche Ltd - Pharmaceutical Division, PDR400